TriangleNCT00514137 · OUTCOME
Event-free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Time from registration to progression or death due to any cause, assessed up to 3 years
What was measured
The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.
Groups in this outcome
Treatment (Kinase Inhibitor Therapy)
Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Treatment (Kinase Inhibitor Therapy) | 13 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Kinase Inhibitor Therapy) | 2.86 | Not reported | 1.35 | 5.52 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.35
- upper Limit
- 5.52
- value
- 2.86
- denoms
- counts
- group Id
- OG000
- value
- 13
- units
- Participants
- description
- The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Treatment (Kinase Inhibitor Therapy)
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Time from registration to progression or death due to any cause, assessed up to 3 years
- title
- Event-free Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice